Previous 10 | Next 10 |
With index investing, there's no escape from a roller coaster ride. For most people, especially retirees, it's very difficult to tolerate large and deep drawdowns. Retirees and conservative investors need income, growth to meet inflation, and most importantly, conservation of capital ...
BBH’s price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and long term. BBH will face some minor ups and downs since most stocks are yet t...
The following slide deck was published by Amgen Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Amgen Inc. 2022 Q1 - Results - Earnings Call Presentation
Amgen Inc. (AMGN) Q1 2022 Results Conference Call April 27, 2022 05:00 PM ET Company Participants Arvind Sood - VP, IR Bob Bradway - Chairman and CEO Peter Griffith - CFO Murdo Gordon - EVP, Global Commercial Operations David Reese - EVP, Research and Development Conference Call Participants ...
Amgen (NASDAQ:AMGN) narrowly exceeded Street forecasts with its 1Q 2022 revenue on Monday as sales volumes surged ~9% YoY offset by 7% YoY lower net selling price. Meanwhile, the first quarter witnessed 2% YoY ($110M) benefit related to estimated sales deductions and the negative impact from ...
Amgen press release (NASDAQ:AMGN): Q1 Non-GAAP EPS of $4.25 beats by $0.12. Revenue of $6.2B (+5.1% Y/Y) beats by $90M. FY2022 total revenues guidance reaffirmed at $25.4B-$26.5B vs. consensus of $26.09B; EPS guidance revised to $12.53-$13.58 on a GAAP basis, and reaffirmed at $17.00-$18.00 o...
AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif. , April 27, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2022. Key results include: Total revenues increased...
HQL pays regular quarterly dividends with a close to double digit yield, and despite poor price growth over medium and long run, HQL’s total return is impressive. In the past three months, a dividend cut and extension of buyback period played a significant role in price movemen...
Amgen (NASDAQ:AMGN) said data from two studies showed that its drug Repatha sustained reduction in 'bad' cholesterol. Data was from two open label extension (OLE) studies to the phase 3 trial, dubbed FOURIER. The FOURIER-OLE studies were composed of trial 20130295 (NCT02867813...
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB) PR Newswire Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 ...
News, Short Squeeze, Breakout and More Instantly...
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
2024-05-17 16:00:07 ET Jay Olson from Oppenheimer issued a price target of $380.00 for AMGN on 2024-05-17 14:37:00. The adjusted price target was set to $380.00. At the time of the announcement, AMGN was trading at $312.32. The overall price target consensus is at $277.3...
Thursday, the FDA approved Amgen Inc’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for the treatment of adult patients with exte...